

Re: Final Programmes of the NZBCS-2017 have been posted online
Your Abstract ID#: 17005

Thank you so much for your participation in the New Zealand Breast Cancer Symposium (NZBCS-2017) - "United for a Cure Through Research", which will be held between the 12th - 14th of November 2017 in Auckland, New Zealand.

The **Final** Programmes of the NZBCS-2017 are now available at the conference website (<http://www.nzbc.org.nz/>). Please visit the following webpage to get the important information about days and times of your oral and/or poster presentations of your accepted abstracts.

<http://www.nzbc.org.nz/keynote-speakers--programme.html>

Session Chairs and Judges: Please check whether you have been invited to serve as a chair for any of the sessions or a judge for the Emerging Scientist oral and poster presentation awards. If so, please make yourself available for the oral and poster sessions.

Please continue to read this email for instructions on your oral and/or poster presentations.

1) Oral Presentations:

Use of personal computers for presentation will not be permitted.

Delegates who are presenting abstracts during a Plenary Session must prepare PowerPoint slides to present their abstracts. Please note you need to bring it on a memory stick (using the USB port in the computer) and upload it on the symposium computers before 7:30am on each day. You can also email your PowerPoint slides to nzbc@aut.ac.nz beforehand (use your abstract ID to name your file). This will not only eliminate the hassle to transfer the file on the day in a hurry, but also let us check the compatibility issues, especially if you are a MAC user. In this case, we will check any potential display issues of your slides and pre-load your PowerPoint slides for you on the symposium computers.

Information on talk time:

- **25 minutes time slots** – please prepare a PowerPoint presentation that lasts for up to 21-22 minutes maximum to allow 3–4 minutes for discussion after your talk.
- **20 minutes time slots** – please prepare a PowerPoint presentation that lasts for up to 15-16 minutes maximum to allow 3–4 minutes for discussion after your talk.
- **15 minutes time slots** – please prepare a PowerPoint presentation that lasts for up to 11–12 minutes maximum to allow 3–4 minutes for discussion after your talk.

Important note for Mac users

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below:

- a) Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
- b) Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).
- c) Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC).

2) Poster-only, Oral-Poster and Poster & Oral presentations:

If your abstract have been selected for Poster-only and Poster & Oral presentations, you are required to be present in front of your poster during the poster secessions on the day allocated.

Oral-Poster: Certain Poster-only abstract may be selected for presentations in an Oral-Poster Presentation Session, if there are time slots available at the final programmes. You will be informed whether your poster has been selected for an Oral-Poster Presentation **by Oct 20, 2017** after we have received the final confirmation of the current oral presenters.

We do not accept electronic posters or e-posters e-posters. Please prepare your traditional printed posters to fit the dimensions below. Our poster boards will accommodate either of the below dimensions:

Poster size: A0, portrait, width × height (841 × 1189 mm, i.e. 33.1 × 46.8 in).

Poster size: A0, landscape, width × height (1189 × 841 mm, i.e. 46.8 × 33.1 in).

If you have any queries and needs any assistance, please send an email to nzbcsc@aut.ac.nz.

Please cite your Abstract ID# 17005 in all correspondences so that we can quickly assist you.

Look forward to meeting you at the conference in November.

Yours sincerely,



A/Prof Dong-Xu Liu

On behalf of the Organising Committee of the NZBCS

Associate Professor Dong-Xu Liu, BSc CAU, MSc CAS, PhD NUS

Chair: Organising Committee of the NZBCS-2017



The synergism of somatostatin, melatonin, retinoids, vitamins E, D3, and C, prolactin and estrogen inhibitors, and metronomic microdoses of cyclophosphamide (Di Bella Method) increased survival, objective response and performance status in a retrospective observational clinical study on 297 cases of breast cancer

Giuseppe Di Bella¹, Biagio Colori², Rosilde Toscano¹

¹Di Bella Foundation, Via Guglielmo Marconi 51, 40122 Bologna, Italy; and ²Rizzoli Scientific Research and Care Institute, Via Giulio Cesare Pupilli, 40136 Bologna, Italy

E-mail: posta@giuseppedibella.it

Key words: breast cancer, somatostatin, estrogen, prolactin, melatonin, retinoids

Improvement of survival, objective response and improved quality of life with a non-toxic biological therapy, considering the fact that breast cancer is still the leading cause of death in women world-wide. The GH / IGF-1 axis is the main mediator of somatic growth, and during puberty it plays an essential role in the development of the mammary gland, regulating cell proliferation, differentiation and apoptosis. Some of the mitogenic effects of GH in the somatic cells are mediated not only by hepatic IGF-1, but also by the induction of the expression of various growth factors, including GH-dependent EGF and VEGF-A. The bond between GH and GHR also activates the signal transduction of various pathways, including JAK-2/STAT, MAPK, and PIK3. This is therefore evidence of the determining role in tumor genesis of the GH / IGF-1 axis and its close receptorial and functional interaction with prolactin, growth factors and mitogenic molecules of the digestive tract, such as VIP, CCK, and Gastrin. Evidence is also emerging of the Estrogen – IGF1 interaction and thus of the central function of IGF as a proliferative modulator common to GH, PRL, and Estrogen. The estrogen-IGF1 axis is involved in mammary hyperplasia in breast cancer and interacts blastically with other endocrine systems such as GH – PRL – IGF1. The mitogenic combination of these endocrine systems confirms the rational and basis of the simultaneous and synergic inhibition of GH in breast cancer by somatostatin, PRL with D2R agonists, estrogen by means of aromatase inhibitors and LH-FSH analogues, and, consequently, of IGF-1, regardless of the expression of ER. The concept of a GH/GF-1/PRL proliferative axis can be extended in breast cancer to a GH/GF/PRL/ER quaternary axis. With MLT, Retinoids, solubilized in vitamin E, D3, and C, Folates, proteoglycans, and calcium, the DBM has a differentiating, cytostatic, anti-angiogenic, immune-modulating, factorially synergic effect, simultaneously reinforcing the functions which physiologists consider to be essential for life. With Somatostatin and/or Octreotide, estrogen and prolactin inhibitors, it has an antiproliferative and anti-angiogenic, antimetastatic interaction, negatively regulating pituitary secretions like GH-PRL. mitogenic properties are enhanced by the combination of ovarian hormones such as estrogen. Complete and stable objective responses without cytolytic chemotherapy, in some cases even without surgery or radiotherapy, with a generalized improvement in quality of life and no significant and/or prolonged toxicity. The most important 5-year survival rate was 69.4% at stage IV cancer versus 26.3% reported by the NCI.

New Zealand Breast Cancer Symposium

--- United for a Cure Through Research ---

November 12th - 14th, 2017, Auckland, New Zealand. Web: www.nzbc.org.nz; Email: nzbc@aut.ac.nz

AUT

Dong-Xu Liu, BSc MSc PhD
Associate Professor
School of Science
Faculty of Health and Environmental
Sciences
Auckland University of Technology
C-42, Private Bag 92006,
Auckland 1142, New Zealand
Tel: +64 9 921 9999 ext. 6722
Mobile: +64 22 612 9452
Fax: +64 9 921 9627
Email: dong-xu.liu@aut.ac.nz

Date: 29 July 2017

Abstract ID#: 17005

First Author: Giuseppe Di Bella

Title of Abstract: The synergism of somatostatin, melatonin, retinoids, vitamins E, D3, and C, prolactin and estrogen inhibitors, and metronomic microdoses of cyclophosphamide (Di Bella Method) increased survival, objective response and performance status in retrospective observational clinical study on 297 cases of breast cancer

Dear Prof Giuseppe Di Bella,

NZBCS-2017: Notification of Abstract Acceptance

Thank you very much for submitting your abstract for presentation at the NZBCS-2017: "New Zealand Breast Cancer Symposium - United for a Cure Through Research" to be held 12-14 November 2017 in Auckland, New Zealand. I am pleased to inform you that your abstract meets the preliminary acceptance requirements set forth by the Scientific Committee and the outcome is as follows:

Your abstract has been accepted for presentation in the format of: oral only; poster only; both oral and poster.

Congratulations - you may start making your conference plans!

Presenting author registration

Confirmation of your abstract on the final program is contingent upon receipt of the presenting author's registration and full payment of fees before 15 October 2017. As of 16 October 2017, your presentation will be dropped from the program if you have not yet registered with fees paid in full and have not contacted the NZBCS-2017 to make other arrangements. You must attend and present the abstract at the conference in order to be included in the program and proceedings.

The preliminary program is posted online (<http://www.nzbc.org.nz>).

Registration is open from 1 April 2017. The registrar at the AUT Hospitality Services will provide confirmation when your registration and fees have been received and processed.

Please note that NZBCS-2017 does not have funds available to pay registration and/or travel expenses for program participants.

Presenting author substitutions

Substitutions for presenting authors may be made until 15 October 2017. The substitute must be registered for the conference at the time of the substitution, must be an original co-author, must not exceed the two-sessions-per person rule, and will be listed as the presenting author in conference materials. Please contact nzbc@aut.ac.nz with the presenting author's name; the substitute's name, e-mail address, organization, country; and the abstract name and ID number. No other changes to your submission are accepted after 15 October 2017.

Poster preparation

Preparation details such as dimensions of the poster board will be provided to you in early October 2017.

Notification of presentation time

You will receive final confirmation of your place on the program as well as the time and date and other information about the poster session in early October 2017 (contingent upon your registration and payment of fees by 15 October 2017).


Questions?

Feel free to contact me on nzbc@aut.ac.nz if you have any questions about your abstract submission or the session.

Please include your abstract ID number when contacting us. This will help us to respond to you most quickly and accurately.

Thank you for your interest, and we look forward to meeting at the NZBCS-2017 in November, Auckland, New Zealand.

Yours sincerely,



A/Prof Dong-Xu Liu, on behalf of the Organising Committee of the NZBCS-2017

*****Please save this message for reference*****